Indirect comparisons of ranibizumab and dexamethasone in macular oedema secondary to retinal vein occlusion

BMC Medical Research Methodology

Volumn 14, Issue 1, 2014, Pages

  Thom, Howard H Z ^a   Capkun, Gorana ^b   Nixon, Richard M ^b   Ferreira, Alberto ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Branch retinal vein occlusion; Central retinal vein occlusion; Dexamethasone; Evidence synthesis; Indirect comparison; Macular oedema; Ranibizumab; Retinal vein occlusion

Indexed keywords

DEXAMETHASONE; RANIBIZUMAB;

ADULT; AGED; BAYES THEOREM; COMPARATIVE STUDY; COMPLICATION; FEMALE; HUMAN; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; STATISTICAL DISTRIBUTION; TREATMENT OUTCOME; VERY ELDERLY; VISUAL ACUITY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BAYES THEOREM; DEXAMETHASONE; FEMALE; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; RANIBIZUMAB; RETINAL VEIN OCCLUSION; STATISTICAL DISTRIBUTIONS; TREATMENT OUTCOME; VISUAL ACUITY; YOUNG ADULT;

EID: 84924141705     PISSN: None     EISSN: 14712288     Source Type: Journal    
DOI: 10.1186/1471-2288-14-140     Document Type: Article

References (26)

1. Klein R: Retinopathy in a population-based study. Trans Am Ophthalmol Soc 1992, 90:561-594.
2. Gewaily D, Greenberg PB: Intravitreal steroids versus observation for macular edema secondary to central retinal vein occlusion. Cochrane Database Syst Rev 2009, 1. http://www.ncbi.nlm.nih.gov/pubmed/19160332.
3. Reshak J, Reshak M: Branch retinal vein occlusion: pathogenisis, visual prognosis, and treatment modalities. Curr Eyes Res 2008, 33: 111-131.
4. Group CRVOS: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 1997, 115:486-491.
5. Group SSR: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6. Arch Ophthalmol 2009, 127:1115-1128.
6. Mohamed Q, McIntosh RL, Saw SM, Wong TY: Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthamology 2007, 114:507-519,524.
7. Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY, Rubio RG: Ranibizumab for macular edema following branch retinal vein occlusion. Six-month primary End point results of a phase III study. Ophthamology 2010, 117:1102-1112.
8. Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, Rundle AC, Rubio RG, Murahashi WY: Ranibizumab for macular edema following central retinal vein occlusion. Six-month primary End point results of a phase III study. Ophthamology 2010, 117:1124-1133.
9. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM; OZURDEX GENEVA Study Group: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema Due to retinal vein occlusion. Ophthamology 2010, 117:1134-1136.
10. Allergan: Dexamethasone Intravitreal Implant (Ozurdex®) for the Treatment of Macular Oedema Caused by Retinal Vein Occlusion. Single Technology Appraisal. London, UK: National Institute for Health and Care Excellence; 2010.
11. Abel K, Black D, Bryden D: TA229 Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion (RVO). NICE Technology Appraisals 2011.
12. Matza LS, Rousculp MD, Malley K, Boye KS, Oglesby A: The longitudinal link between visual acuity and health-related quality of life in patients with diabetic retinopathy. Health Qual Life Outcomes 2008, 6. http://www.hqlo.com/content/6/1/95.
13. Kinge B, Stordahl PB, Forsaa V, Fossen K, Haugstad M, Helgesen OH, Seland J, Stene-Johansen I: Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmology 2010, 150:310-314.
14. NICE: Single Technology Appraisal (STA). Specification for Manufacturer/Sponsor Submission of Evidence. National Institute for Health and Clinical Excellence; 2009.
15. Lasdon LS, Waren AD, Jain A, Ratner M: Design and testing of a generalized reduced gradient code for nonlinear programming. ACM Transactions on Mathematical Software 1978, 4:34-50.
16. Ades A, Mavranezouli M, Dias S, Welton N, Whittington C, Kendall T: Network meta-analysis with competing risk outcomes. Value Health 2010, 13:976-983.
17. Trikalinos T, Olkin I: A method for the meta-analysis of mutually exclusive binary outcomes. Statistcs in Medicine 2008, 27:4279-4300.
18. Dias S, Welton NJ, Sutton AJ, Ades AE: NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials, 2011. National Institute for Health and Care Excellence; 2014. last updated April 2014; available from http://www.nicedsu.org.uk.
19. Bucher HC, Guyett GH, Griffith LE, Walter SD: The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997, 50:683-691.
20. Lunn DJ, Thomas A, Best N, Spiegelhalter D: WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Statistics and Computing 2000, 10:325-337.
21. Caldwell DM, Ades AE, Higgins JPT: Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331:897-900.
22. Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23:3105-3124.
23. Welton NJ, Sutton AJ, Cooper NJ, Abrams KR, Ades AE: Evidence Synthesis for Decision Making in Healthcare. Chichester, West Sussex, UK: John Wiley and Sons; 2012.
24. Sweeting MJ, Sutton AJ, Lambert PC: What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004, 23: 1351-1375.
25. Sutton A, Ades AE, Cooper N, Abrams K: Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 2008, 26:753-767.
26. Turner RM, Spiegelhalter DJ: Bias modelling in evidence synthesis. JR Statist Soc A 2009, 172:21-47.